Edgewise Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 38.9 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 4.22B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Details
| Name | Edgewise Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 127 |
| Founded | 2017 |
| Ipo Date | 2021-03-26 |
| Ceo | Kevin Koch |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 16.00 |
| Isin | US28036F1057 |
| Cusip | 28036F105 |
| Cik | 1710072 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Kevin Koch Ph.D. | President, Chief Executive Officer and Director |
| Dr. Peter A. Thompson FACP, M.D. | Co-Founder and Independent Chairman |
| Dr. Badreddin Edris Ph.D. | Co-Founder and Independent Director |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer and Director |
| Michael P. Nofi | Chief Financial Officer |
| Dr. Behrad Derakhshan Ph.D. | Chief Operating Officer |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer |
| John R. Moore J.D. | General Counsel |
| Dr. Aylin Tugcu | Senior Vice President of Cardiovascular Clinical Development and Medical Affairs |
Contact
| Address | 1715 38th Street, Boulder, Colorado 80301, United States |
| Phone | 720 262 7002 |
| Website | https://edgewisetx.com |